ATE253576T1 - 8-chinolinxanthin and 8-isochinolinxanthin derivate als pde 5 inhibitoren - Google Patents

8-chinolinxanthin and 8-isochinolinxanthin derivate als pde 5 inhibitoren

Info

Publication number: ATE253576T1
Authority: AT; Austria
Prior art keywords: quinolinxanthine; isochinolinxanthine; pde; inhibitors; derivatives
Prior art date: 2000-04-07

Application number

AT01940294T

Other languages

English (en)

Inventor

Gurdip Bhalay

Stephen Paul Collingwood

Robin Alec Fairhurst

Sylvie Felicite Gomez

Reto Naef

David Andrew Sandham

Original Assignee

Novartis Ag

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-07

Filing date

2001-04-05

Publication date

2003-11-15

2001-04-05 Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag

2003-11-15 Application granted granted Critical

2003-11-15 Publication of ATE253576T1 publication Critical patent/ATE253576T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Gynecology & Obstetrics (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pregnancy & Childbirth (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)

AT01940294T 2000-04-07 2001-04-05 8-chinolinxanthin and 8-isochinolinxanthin derivate als pde 5 inhibitoren ATE253576T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0008694.2A GB0008694D0 (en)	2000-04-07	2000-04-07	Organic compounds
PCT/EP2001/003909 WO2001077110A1 (en)	2000-04-07	2001-04-05	8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors

Publications (1)

Publication Number	Publication Date
ATE253576T1 true ATE253576T1 (de)	2003-11-15

Family

ID=9889516

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01940294T ATE253576T1 (de)	2000-04-07	2001-04-05	8-chinolinxanthin and 8-isochinolinxanthin derivate als pde 5 inhibitoren

Country Status (29)

Country	Link
US (1)	US20030171384A1 (de)
EP (1)	EP1268480B1 (de)
JP (1)	JP3869725B2 (de)
KR (1)	KR100526094B1 (de)
CN (1)	CN1176922C (de)
AR (1)	AR028531A1 (de)
AT (1)	ATE253576T1 (de)
AU (2)	AU2001273921B2 (de)
BR (1)	BR0109855A (de)
CA (1)	CA2403514C (de)
CZ (1)	CZ20023305A3 (de)
DE (1)	DE60101158T2 (de)
DK (1)	DK1268480T3 (de)
ES (1)	ES2210169T3 (de)
GB (1)	GB0008694D0 (de)
HU (1)	HUP0300565A3 (de)
IL (1)	IL152078A0 (de)
MX (1)	MXPA02009903A (de)
MY (1)	MY119238A (de)
NO (1)	NO20024741D0 (de)
NZ (1)	NZ521361A (de)
PE (1)	PE20020228A1 (de)
PL (1)	PL212407B1 (de)
PT (1)	PT1268480E (de)
RU (1)	RU2269529C2 (de)
SK (1)	SK14282002A3 (de)
TR (1)	TR200400185T4 (de)
WO (1)	WO2001077110A1 (de)
ZA (1)	ZA200207956B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10135815A1 (de) *	2001-07-23	2003-02-06	Bayer Ag	Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
US7019010B2 (en) *	2001-09-27	2006-03-28	Novertis Ag	Combinations
EP1515972B1 (de)	2002-06-12	2009-05-13	F. Hoffmann-La Roche Ag	Amid substituierte xanthin derivate mit gluconeogenesis modulierender wirkung
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DK1532149T3 (da) *	2002-08-21	2010-05-10	Boehringer Ingelheim Pharma	8-[3-amino-piperiden-1-yl]-xanthiner, fremstilling deraf og anvendelse deraf som lægemiddel
CN100361992C (zh) *	2003-02-19	2008-01-16	霍夫曼-拉罗奇有限公司	用作pepck抑制剂的磺酰胺取代的黄嘌呤
US7148229B2 (en)	2003-02-19	2006-12-12	Hoffman-La Roche Inc.	Sulfonamide substituted xanthine derivatives
CA2528385C (en) *	2003-06-06	2011-03-15	Endacea, Inc.	A1 adenosine receptor antogonists
KR100658080B1 (ko) *	2003-08-26	2006-12-15	비오이 하이디스 테크놀로지 주식회사	백라이트 조립용 지그
TW200605893A (en) *	2004-02-12	2006-02-16	Novartis Ag	Use of organic compounds
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
JP5220407B2 (ja) *	2004-05-08	2013-06-26	ノバルティス・インターナショナル・ファーマシューティカル・リミテッド	１−アリール−４−置換イソキノリン類
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005001989A1 (de) *	2005-01-15	2006-07-20	Bayer Healthcare Ag	Intravenöse Formulierungen von PDE-Inhibitoren
WO2006091896A2 (en) *	2005-02-25	2006-08-31	Adenosine Therapeutics, Llc	Pyridyl substituted xanthines
WO2006104870A2 (en) *	2005-03-25	2006-10-05	Schering Corporation	Methods of treating benign prostatic hyperplasia or lower urinary track symptoms by using pde 5 inhibitors
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070225217A1 (en)	2005-11-09	2007-09-27	Combinatorx, Incorporated	Methods, compositions, and kits for the treatment of medical conditions
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP1852108A1 (de)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Zusammensetzungen von DPP-IV-Inhibitoren
MX2008014024A (es)	2006-05-04	2008-11-14	Boehringer Ingelheim Int	Formas poliformas.
KR20100029762A (ko) *	2007-06-13	2010-03-17	바이엘 쉐링 파마 악티엔게젤샤프트	청력 장애 치료용 ｐｄｅ 억제제
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
MX2011002558A (es)	2008-09-10	2011-04-26	Boehringer Ingelheim Int	Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (de)	2008-12-23	2011-11-02	Boehringer Ingelheim International GmbH	Salzformen einer organischen verbindung
TW201036975A (en)	2009-01-07	2010-10-16	Boehringer Ingelheim Int	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
CN102361557A (zh) *	2009-03-26	2012-02-22	Mapi医药公司	制备阿格列汀的方法
EP3646859A1 (de)	2009-11-27	2020-05-06	Boehringer Ingelheim International GmbH	Behandlung von genotypisierten diabetes-patienten mit dpp-iv-hemmern wie etwa linagliptin
AU2011249722B2 (en)	2010-05-05	2015-09-17	Boehringer Ingelheim International Gmbh	Combination therapy
CN106975074A (zh)	2010-06-24	2017-07-25	勃林格殷格翰国际有限公司	糖尿病治疗
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN103476757A (zh) *	2011-02-18	2013-12-25	阿勒根公司	作为磷酸二酯酶10(pde10a)的抑制剂的取代的6,7-二烷氧基-3-异喹啉醇衍生物
PH12014500137A1 (en)	2011-07-15	2017-08-18	Boehringer Ingelheim Int	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
WO2013171167A1 (en)	2012-05-14	2013-11-21	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
US20130303554A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014071044A1 (en) *	2012-11-01	2014-05-08	Allergan, Inc.	Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
EP3110449B1 (de)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Medizinische verwendung eines dpp-4-inhibitors
WO2017211979A1 (en)	2016-06-10	2017-12-14	Boehringer Ingelheim International Gmbh	Combinations of linagliptin and metformin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2531085A1 (fr) *	1982-07-28	1984-02-03	Adir	Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant
FR2558162B1 (fr) *	1984-01-17	1986-04-25	Adir	Nouveaux derives de la xanthine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
TW252044B (de) *	1992-08-10	1995-07-21	Boehringer Ingelheim Kg
GB9301192D0 (en) *	1993-06-09	1993-06-09	Trott Francis W	Flower shaped mechanised table
WO1999062905A1 (en) *	1998-06-03	1999-12-09	Almirall Prodesfarma, S.A.	8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
GB9828340D0 (en) *	1998-12-22	1999-02-17	Novartis Ag	Organic compounds

2000
- 2000-04-07 GB GBGB0008694.2A patent/GB0008694D0/en not_active Ceased
2001
- 2001-04-05 NZ NZ521361A patent/NZ521361A/en unknown
- 2001-04-05 PL PL358205A patent/PL212407B1/pl unknown
- 2001-04-05 AR ARP010101623A patent/AR028531A1/es not_active Application Discontinuation
- 2001-04-05 AU AU2001273921A patent/AU2001273921B2/en not_active Ceased
- 2001-04-05 DK DK01940294T patent/DK1268480T3/da active
- 2001-04-05 SK SK1428-2002A patent/SK14282002A3/sk unknown
- 2001-04-05 RU RU2002129557/04A patent/RU2269529C2/ru not_active IP Right Cessation
- 2001-04-05 AT AT01940294T patent/ATE253576T1/de active
- 2001-04-05 CA CA002403514A patent/CA2403514C/en not_active Expired - Fee Related
- 2001-04-05 WO PCT/EP2001/003909 patent/WO2001077110A1/en not_active Ceased
- 2001-04-05 MX MXPA02009903A patent/MXPA02009903A/es active IP Right Grant
- 2001-04-05 DE DE60101158T patent/DE60101158T2/de not_active Expired - Lifetime
- 2001-04-05 US US10/240,481 patent/US20030171384A1/en not_active Abandoned
- 2001-04-05 KR KR10-2002-7012627A patent/KR100526094B1/ko not_active Expired - Fee Related
- 2001-04-05 IL IL15207801A patent/IL152078A0/xx unknown
- 2001-04-05 JP JP2001575583A patent/JP3869725B2/ja not_active Expired - Fee Related
- 2001-04-05 EP EP01940294A patent/EP1268480B1/de not_active Expired - Lifetime
- 2001-04-05 BR BR0109855-1A patent/BR0109855A/pt not_active IP Right Cessation
- 2001-04-05 HU HU0300565A patent/HUP0300565A3/hu unknown
- 2001-04-05 PT PT01940294T patent/PT1268480E/pt unknown
- 2001-04-05 PE PE2001000317A patent/PE20020228A1/es not_active Application Discontinuation
- 2001-04-05 AU AU7392101A patent/AU7392101A/xx active Pending
- 2001-04-05 ES ES01940294T patent/ES2210169T3/es not_active Expired - Lifetime
- 2001-04-05 CZ CZ20023305A patent/CZ20023305A3/cs unknown
- 2001-04-05 MY MYPI20011632A patent/MY119238A/en unknown
- 2001-04-05 CN CNB018074898A patent/CN1176922C/zh not_active Expired - Fee Related
- 2001-04-05 TR TR2004/00185T patent/TR200400185T4/xx unknown
2002
- 2002-10-02 NO NO20024741A patent/NO20024741D0/no not_active Application Discontinuation
- 2002-10-03 ZA ZA200207956A patent/ZA200207956B/en unknown

Also Published As

Publication number	Publication date
WO2001077110A1 (en)	2001-10-18
EP1268480A1 (de)	2003-01-02
PL358205A1 (en)	2004-08-09
DK1268480T3 (da)	2004-03-15
AR028531A1 (es)	2003-05-14
DE60101158D1 (en)	2003-12-11
JP3869725B2 (ja)	2007-01-17
EP1268480B1 (de)	2003-11-05
CA2403514C (en)	2010-01-12
GB0008694D0 (en)	2000-05-31
CA2403514A1 (en)	2001-10-18
PE20020228A1 (es)	2002-03-28
NZ521361A (en)	2004-05-28
ES2210169T3 (es)	2004-07-01
AU2001273921B2 (en)	2005-05-05
KR100526094B1 (ko)	2005-11-08
US20030171384A1 (en)	2003-09-11
RU2002129557A (ru)	2004-03-27
PT1268480E (pt)	2004-03-31
NO20024741L (no)	2002-10-02
CN1176922C (zh)	2004-11-24
DE60101158T2 (de)	2004-08-26
IL152078A0 (en)	2003-05-29
HUP0300565A3 (en)	2004-10-28
CN1420887A (zh)	2003-05-28
MY119238A (en)	2005-04-30
RU2269529C2 (ru)	2006-02-10
PL212407B1 (pl)	2012-09-28
KR20020081590A (ko)	2002-10-28
TR200400185T4 (tr)	2004-03-22
CZ20023305A3 (cs)	2003-01-15
MXPA02009903A (es)	2003-03-27
ZA200207956B (en)	2003-07-16
BR0109855A (pt)	2003-06-03
NO20024741D0 (no)	2002-10-02
SK14282002A3 (sk)	2003-04-01
JP2003530398A (ja)	2003-10-14
AU7392101A (en)	2001-10-23
HUP0300565A2 (hu)	2003-07-28

Publication	Publication Date	Title
ATE253576T1 (de)	2003-11-15	8-chinolinxanthin and 8-isochinolinxanthin derivate als pde 5 inhibitoren
ATE437862T1 (de)	2009-08-15	Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
ATE256127T1 (de)	2003-12-15	Betacarbolinderivate als phosphodiesterase- inhibitoren
DE60032601D1 (de)	2007-02-08	Als antikrebsmittel verwendbare heterocyklische derivate
DE60106252D1 (de)	2004-11-11	Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
ATE370137T1 (de)	2007-09-15	4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
IS6934A (is)	2003-08-29	Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
AR028567A1 (es)	2003-05-14	Nuevos derivados de fenil-propargileter
EE200100492A (et)	2002-12-16	Ensüümi IMPDH inhibiitorid
DE60031513D1 (de)	2006-12-07	Phenyl- und pyridinyl-derivate verwendbar als neurokinin-1-antagonisten
DE60009147D1 (de)	2004-04-22	Admantan derivate
ATE433451T1 (de)	2009-06-15	Xanthin-phosphodiesteras-v-inhibitoren
AR028253A1 (es)	2003-04-30	Inhibidores de la glucogeno fosforilasa
EE200200715A (et)	2004-08-16	Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
AR028596A1 (es)	2003-05-14	Nuevos derivados de fenilglicina
DE60105020D1 (de)	2004-09-23	6-phenylpyrrolopyrimidindion derivate
ATE298332T1 (de)	2005-07-15	Decahydro-isochinolinderivate
ATE273962T1 (de)	2004-09-15	5-phenyl-pyrimidine derivate
DE60203529D1 (de)	2005-05-04	Indolderivate als cox-ii-inhibitoren
DE69814894D1 (de)	2003-06-26	Isochinolin derivate als urokinase inhibitoren
DE60231897D1 (de)	2009-05-20	Triazol derivate als cyclooxygenase inhibitoren
DE60025918D1 (de)	2006-04-20	4-phenyl-pyrimidine derivate
PT1322592E (pt)	2004-12-31	Derivados substituidos de 1-aminobutan-3-ol
ATE280752T1 (de)	2004-11-15	Aminomethyl-phenyl-cyclohexanonderivate
EE200200389A (et)	2003-10-15	Imidasooli uued derivaadid

Legal Events

Date	Code	Title	Description
2004-08-15	UEP	Publication of translation of european patent specification	Ref document number: 1268480 Country of ref document: EP

Date

Code

Title

Description

2004-08-15

UEP

Publication of translation of european patent specification

Ref document number: 1268480

Country of ref document: EP